Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Holding FOLD?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.02Last Year’s EPS
-$0.11Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -16.52%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call displayed a positive sentiment with strong revenue growth, successful product launches, increased guidance, and achievement of non-GAAP profitability. While there are challenges like ongoing litigation and a decrease in cash reserves, they are outweighed by the strong financial and operational performance.Company Guidance
During the third quarter of 2024, Amicus Therapeutics demonstrated strong financial performance and provided updated guidance for the rest of the year. The company reported a total revenue of $142 million, reflecting a 37% year-over-year growth, and increased its full-year revenue guidance to 30% to 32%. Galafold, a key product, generated $120 million in revenue, marking a 19% growth from the previous year, with patient compliance rates exceeding 90%. Amicus also raised its full-year revenue guidance for Pombiliti and Opfolda to $69 million-$71 million following a successful global launch. The company achieved non-GAAP profitability and reduced its operating expense guidance to $340 million-$350 million. Amicus settled a key IP litigation with Teva, reinforcing its confidence in the strength of its intellectual property, while continuing to expand market access and pursue regulatory submissions for its products globally.Strong Revenue Growth
Amicus Therapeutics reported total revenue of $142 million in Q3 2024, representing a 37% year-over-year growth. Galafold revenue grew by 19% year-over-year at constant currency.
Galafold Performance
Galafold reported $120 million in global revenue for the quarter and achieved over 60% global market share of treated Fabry patients with amenable mutations.
Pombiliti and Opfolda Launch
New therapy for late-onset Pompe disease, Pombiliti and Opfolda, reported revenue of $21 million, a 33% increase compared to Q2 2024.
Increased Revenue Guidance
Amicus Therapeutics increased its full-year 2024 total revenue guidance to 30%-32% growth.
Non-GAAP Profitability
The company achieved non-GAAP profitability for the full year as of Q3 2024.
---
FOLD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FOLD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $11.74 | $11.24 | -4.26% |
| Aug 08, 2024 | $10.00 | $11.32 | +13.20% |
| May 09, 2024 | $10.14 | $9.48 | -6.51% |
| Feb 28, 2024 | $13.85 | $12.95 | -6.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amicus Therapeutics (FOLD) report earnings?
Amicus Therapeutics (FOLD) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Amicus Therapeutics (FOLD) earnings time?
Amicus Therapeutics (FOLD) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FOLD EPS forecast?
FOLD EPS forecast for the fiscal quarter 2024 (Q4) is $0.02.
---